Nasdaq GlobeNewswire

IPsoft Equips Businesses to Accelerate Digital Transformation at Scale by Automating Delivery of Enterprise Services with 1Desk(TM)

Del

1Desk(TM), the world's first AI platform to combine cognitive and autonomic technologies, will fully automate shared enterprise services

NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- IPsoft, the leader in enterprise AI, today announced its visionary new platform for business users, 1Desk(TM), that enables businesses to accelerate digital transformation and stay competitive in the digital economy. For the first time, enterprises will be able to draw on a digital labor pool of cognitive agents, virtual engineers and virtual administrators in order to automate entire end-to-end processes, from HR and IT, to Finance and Administration. Employees will no longer have to navigate multiple systems but instead channel all their requests and queries through a single cognitively-enabled interface to access a full suite of enterprise services 24-by-7.

Although the average cost of Selling, General and Administrative (SG&A) expenses across industries sits at around 25% of sales1, this can be considerably higher in major industries including Financial Services (41%) and Healthcare (38%). The level of automation made possible by 1Desk(TM) could cut this to a fraction of the cost. At the same time, employee productivity is set to rise sharply as dedicated personal digital support will eliminate the time wasted by filling out cumbersome forms and waiting for routine tasks to be completed.

"1Desk(TM) is the unified service desk that converges the front and back offices. It directly connects business users to the applications that service them, disintermediating large segments of IT and business operations. 1Desk(TM) improves the Net Promoter Scores not only for IT, but for HR, finance, helpdesk, facilities and administrative tasks. The big difference to 1Desk(TM) is that it has cognitive competence so it can understand business users directly, and service their requests through automated digital labor, not by armies of people," said Chetan Dube, CEO of IPsoft.

Uniquely, 1Desk(TM) will be able to target the inefficiencies that lie in processes running across different functions. For example, the comprehensive process knowledge capabilities of Amelia, IPsoft's market-leading cognitive agent embedded in the 1Desk(TM) platform, can act as the glue to unify the implications of policy changes across all supporting enterprise systems by automatically updating intelligent workflows.

In the $6.3 trillion2 race for digital renovation, manual processes have become a stumbling block for operational efficiency and market growth. Static point solutions that automate single steps in the process limit the speed of change that is required to compete with companies that were 'born-digital' as well as traditional competitors that are on a fast track to digital adoption. Through machine learning, 1Desk(TM) facilitates rapid improvement and industrializes a cycle of continuous improvement and learning from every interaction with business users. Exceptions that are managed by human engineers and administrators within 1Desk(TM) are recorded at all times so that a stream of new intelligent automation is generated, speeding up the ability to implement new efficiencies going forward.

Carestream Health, a global provider of medical imaging systems and IT solutions, will be the first Beta customer for 1Desk(TM). "1Desk(TM) introduces AI innovation on a grand scale, opening up the possibility to set a new standard for cognitive-enabled business processes in terms of both speed and quality," said Gerson Benker, Vice President of IT Operations at Carestream. "We are excited at the prospect of employing 1Desk(TM)'s end-to-end automation capabilities within our strategy in order to provide an even better experience for our business users and customers."

The vastly increased automation of business processes enabled by 1Desk(TM) represents a radical shift in the operating model for enterprise organizational models. In the future, the execution of tasks will be predominantly fulfilled by Digital Labor. Human talent will focus on managing and directing the further development of automation. IPsoft facilitates the creation of a Digital Labor Studio within organizations to orchestrate the rapid development of a continuously improving Digital Workforce. This unique hub of digital enablement talent will coordinate the work of automation engineers, data scientists, linguists, business analysts, user-experience designers and system integrators to deliver on the full value of 1Desk(TM).

1Desk(TM) is created on a foundation of market-leading technology. Amelia is widely recognized as being at the forefront of conversational AI platforms and was recently described by industry analyst firm Ovum as being uniquely suitable for enabling entirely new customer channels. IPsoft's autonomic technology has been spearheading transformation at scale for more than 15 years and is noted by research analyst Everest Group as the leader in IT automation.

1  SG&A Benchmarks, Schonfield & Associates 2 IDC Worldwide Semiannual Digital Transformation Spending Guide, May 2017

About IPsoft
IPsoft, the leader in enterprise AI, automates IT and business processes for enterprises across a wide range of industries by deploying Digital Labor. Through its portfolio of world leading autonomic and cognitive solutions, IPsoft provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has 18 offices in 15 countries across the world and serves more than 500 of the world's leading brands directly as well as more than half of the world's largest IT services providers.

Contact
IPsoft
Daniela Zuin, +1 212 708 5521 
Marketing Director, IPsoft
daniela.zuin@ipsoft.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPsoft via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressemelding

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressemelding

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressemelding

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom